

A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin) (SkybriGHT)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Up to 18 years old

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 1 to 18 years old - on treatment with SKYTROFA (lonapegsomatropin)

Exclusion Criteria:

- participating in any interventional clinical study

Conditions & Interventions

Interventions:

Other: No intervention

Conditions:

Rare Diseases

Keywords:

growth hormone, growth hormone deficiency

More Information

Description: Skytrofa is approved in the U.S. for sale and use in children with growth hormone deficiency (GHD). This study is being done to find out how safe and useful Skytrofa is for long-term treatment. A child's care will follow the normal treatment practices at the clinic. There is no new treatment or medicine involved and no additional visits will be performed.

Study Contact: Brad Miller - mille685@umn.edu

Principal Investigator: Brad Miller, MD, PhD

IRB

Number: SITE00002031

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.